Rekvina Laboratories Opens Offer for Acquisition of up to 28,90,100 Equity Shares from the Public
Rekvina Laboratories Limited has launched an Open Offer for the acquisition of equity shares from public shareholders. The offer is being managed by Vivro Financial Services Private Limited on behalf of Surbhit Mukesh Shah (Acquirer-1), Amit Mukesh Shah (Acquirer-2), and Dhruvalkumar Patel (Acquirer-3) (collectively referred to as "Acquirers").The open offer concerns up to 28,90,100 fully paid-up equity shares of Rekvina Laboratories Limited, each having a face value of Rs 5/-. These shares represent 26% of the Expanded Share Capital of the company. The offer period is scheduled from July 1, 2026, to July 14, 2026.
Acquirer-1 and Acquirer-2 are current members of the Promoter Group of Rekvina Laboratories Limited, while Acquirer-3 is set to be classified as a joint Promoter along with the existing Promoter group members. Post completion of the Open Offer and after the acquisition of Subscription Shares under the Underlying Transaction, the collective shareholding of the Acquirers, along with other members of the Promoter and Promoter group, is projected to reach 85,59,096 Equity Shares, which represents 77.00% of the Expanded Share Capital of the company.
Acquisition Details and Financials
The offer details indicate that a total of 28,90,100 Equity Shares were offered for acquisition in the Open Offer component. The financial aggregate of the Offer is detailed as follows:| Metric | Value |
|---|---|
| Total Aggregate Number of Equity Shares Tendered | 28,90,100 |
| Size of the Offer (Total consideration) | Rs 2,89,01,000/- |
| Pre-Offer Shareholding of Acquirers and PAC | 35.38% |
The acquisition details related to shares issued by way of swap under an underlying transaction are presented in the table below:
| Investor Name | No. of Securities Issued | Type of Securities | Total Consideration Against Issue (Swap) |
|---|---|---|---|
| Surbhit Mukesh Shah | 15,56,250 | Equity Shares | Rs 6,22,500 |
| Amit Mukesh Shah | 21,81,250 | Equity Shares | Rs 8,72,500 |
| Ami Amit Shah | 3,33,845 | Equity Shares | Rs 1,33,538 |
| Krima Surbhit Shah | 3,33,843 | Equity Shares | Rs 1,33,537 |
| Dhruvalkumar Patel | 2,22,562 | Equity Shares | Rs 89,025 |
| Total | 46,27,750 | Rs 18,51,100 |
The acquisition of shares through the Open Offer component is expected to result in an increase in shareholding as follows:
| Metric | Pre-Offer Shareholding (Acquirers and PAC) | Post-Offer Shareholding (Acquirers and PAC) |
|---|---|---|
| % of Expanded Share Capital | 25.56% | 30.17% |
Contextual Information
The Open Offer is part of the broader corporate actions related to Rekvina Laboratories Limited, which includes a contemplated Underlying Transaction under SEPA. The underlying transaction and allotment of equity shares are contingent on receiving approval for the proposed Preferential Issue by the BSE.The Post-Offer Advertisement, issued by Vivro Financial Services Private Limited, must be read in conjunction with several previous documents:
- A Public Announcement dated March 16, 2026.
- A Detailed Public Statement dated March 23, 2026, published on March 24, 2026.
- The Letter of Offer dated June 20, 2026.
- A Pre-Offer Advertisement cum Corrigendum dated June 29, 2026, published on June 30, 2026.
Stock Price Movement
As of 13:44, Rekvina Laboratories Ltd. shares are edging lower, standing at ₹25.00 in response to a 0.99% drop. The stock remains completely flat as the intraday high and low are both held precisely at the current trading level of ₹25.00.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.